COMMUNIQUÉS West-GlobeNewswire

MEDVI Quad Prescription Information Updated as Consumer Interest in Prescription Erectile Dysfunction Treatment Access Through Telehealth Platforms Grows in 2026
28/01/2026
An informational overview examining category context, publicly available service disclosures, and what consumers often consider when researching prescription erectile dysfunction treatment access through telehealth [...]
Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma
28/01/2026
FORT LEE, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2026
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
28/01/2026
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/ [...]
Future Communities Institute, with Akido Labs, Five Keys, and ReImagine Freedom Launch the Bay Area’s First AI-Powered Safety Net Program
28/01/2026
Delivering an Abundance of Personalized, High-Quality Care to the Region’s Vulnerable Communities and People Experiencing Homelessness SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Future Communities Institute (FCI) [...]
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
28/01/2026
SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s [...]
GUERBET : Karim Boussebaa nommé Directeur général
28/01/2026
Karim Boussebaa nommé Directeur général de Guerbet Villepinte, le 28 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination [...]
Guerbet: Karim Boussebaa appointed Chief Executive Officer
28/01/2026
Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment [...]
Memorial Şişli Hospital Earns EARL “Theranostics Center of Excellence” for Nuclear Oncology Treatments
28/01/2026
ISTANBUL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Memorial Şişli Hospital’s (part of Memorial Hospitals Group ) Nuclear Medicine Department, Theranostics Unit has successfully completed the evaluation process under the [...]
NADP Foundation Announces 2026 Grants
28/01/2026
DALLAS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) Foundation is pleased to announce the recipients of its 2026 grant awards, supporting innovative projects that improve access to [...]
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
28/01/2026
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
28/01/2026
Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated [...]
NetraMark Closes First Tranche of Private Placement
28/01/2026
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
Bay Alarm Medical Celebrates 16,500 5-Star Google Reviews, Reinforcing Role as Best Medical Alert System
28/01/2026
Milestone underscores the company’s commitment to safety, service, and dependable emergency response for aging adults across the U.S. Concord, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Bay Alarm Medical , a nationwide [...]
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
28/01/2026
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
28/01/2026
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE [...]
Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals
28/01/2026
Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United States Patent and [...]
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
28/01/2026
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences , Inc., (“Life Bio”) a [...]
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
28/01/2026
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this [...]

Pages